Published in final edited form as:

Gastroenterology. 2013 May ; 144(5): 1042–1054.e4. doi:10.1053/j.gastro.2013.01.056.

Transforming Growth Factor- β Signaling in Hepatocytes Promotes Hepatic Fibrosis and Carcinogenesis in Mice With Hepatocyte-Specific Deletion of TAK1

LING YANG^{1,2}, SAYAKA INOKUCHI¹, YOON SEOK ROH¹, JINGYI SONG¹, ROHIT LOOMBA¹, EEK JOONG PARK¹, and EKIHIRO SEKI¹

¹Division of Gastroenterology, Department of Medicine, University of California, San Diego, School of Medicine, La Jolla, California and ²Division of Gastroenterology, Department of Internal Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

Abstract

BACKGROUND & AIMS—Transforming growth factor (TGF)- β -activated kinase 1 (TAK1) is activated in different cytokine signaling pathways. Deletion of *Tak1* from hepatocytes results in spontaneous development of hepatocellular carcinoma (HCC), liver inflammation, and fibrosis. TGF- β activates TAK1 and Smad signaling, which regulate cell death, proliferation, and carcinogenesis. However, it is not clear whether TGF- β signaling in hepatocytes, via TGF- β receptor-2 (*Tgfr2*), promotes HCC and liver fibrosis.

METHODS—We generated mice with hepatocyte-specific deletion of *Tak1* (*Tak1 Δ Hep*), as well as *Tak1/Tgfr2 Δ Hep* and *Tak1/Smad4 Δ Hep* mice. *Tak1flox/flox*, *Tgfr2 Δ Hep*, and *Smad4 Δ Hep* mice were used as controls, respectively. We assessed development of liver injury, inflammation, fibrosis, and HCC. Primary hepatocytes isolated from these mice were used to assess TGF- β -mediated signaling.

RESULTS—Levels of TGF- β , TGF- β R2, and phospho-Smad2/3 were increased in HCCs from *Tak1 Δ Hep* mice, which developed liver fibrosis and inflammation by 1 month and HCC by 9 months. However, *Tak1/Tgfr2 Δ Hep* mice did not have this phenotype, and their hepatocytes did not undergo spontaneous cell death or compensatory proliferation. Hepatocytes from *Tak1 Δ Hep* mice incubated with TGF- β did not activate p38, c-Jun N-terminal kinase, or nuclear factor- κ B; conversely, TGF- β -mediated cell death and phosphorylation of Smad2/3 were increased, compared with control hepatocytes. Blocking the Smad pathway inhibited TGF- β -mediated death of *Tak1*-/- hepatocytes. Accordingly, disruption of *Smad4* reduced the spontaneous liver injury, inflammation, fibrosis, and HCC that develops in *Tak1 Δ Hep* mice. Levels of the anti-apoptotic protein Bcl-xL, β -catenin, connective tissue growth factor, and vascular endothelial growth factor were increased in HCC from *Tak1 Δ Hep* mice, but not in HCCs from *Tak1/Tgfr2 Δ Hep* mice.

© 2013 by the AGA Institute

Reprint requests Address requests for reprints to: Ekihiro Seki, MD, PhD, Division of Gastroenterology, Department of Medicine, University of California San Diego, School of Medicine, 9500 Gilman Drive, MC#0702, Leichtag Biomedical Research Building Room#118B, La Jolla, California 92093-0702. ekseki@ucsd.edu; fax: 858-822-5370. .

Author names in bold designate shared co-first authorship.

Conflicts of interest The authors disclose no conflicts.

Supplementary Materials Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at www.gastrojournal.org, and at <http://dx.doi.org/10.1053/j.gastro.2013.01.056>.

Injection of N-nitrosodiethylamine induced HCC formation in wild-type mice, but less in *Tgfbr2 Δ Hep* mice.

CONCLUSIONS—TGF- β promotes development of HCC in *Tak1 Δ Hep* mice by inducing hepatocyte apoptosis and compensatory proliferation during early phases of tumorigenesis, and inducing expression of anti-apoptotic, pro-oncogenic, and angiogenic factors during tumor progression.

Keywords

Liver Cancer; Mouse Model; Signal Transduction; Oncogene

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths in the United States.¹ The increasing incidence of HCC is a result of the increased prevalence of hepatitis C virus infection, alcoholic cirrhosis, and nonalcoholic steatohepatitis. In humans, development of HCC is associated with chronic liver inflammation, fibrosis, and its subsequent irreversible cirrhosis.¹ In contrast, a mouse model for liver fibrosis induced by carbon tetrachloride does not induce HCC, and a mouse model for carcinogen-induced HCC is not accompanied by fibrosis. The current lack of an ideal animal model for liver fibrosis-associated HCC limits the mechanistic study of HCC.² We and others have recently established a mouse model that spontaneously develops HCC accompanied by liver fibrosis by deleting *Tak1* in hepatocytes, indicating that TAK1 is a tumor suppressor in the liver.^{3,4}

Transforming growth factor- β (TGF- β)-activated kinase 1 (TAK1) is activated in various cytokine signaling, such as tumor necrosis factor (TNF), interleukin (IL)-1, Toll-like receptors, and transforming growth factor (TGF)- β . TAK1 then activates downstream kinases such as I κ B kinase (IKK), c-Jun-N-terminal kinase (JNK), and p38 that regulate cell survival, proliferation, and tumor growth.^{5,6} TNF receptor signaling activates both TAK1-IKK-nuclear factor- κ B (NF- κ B) pathway and caspase-mediated cell death pathway.⁷ Inactivation of TAK1 increases the susceptibility of hepatocytes to TNF-induced cell death through overactivation of caspases caused by lack of the TAK1-IKK-NF- κ B activation.³ Notably, deletion of TNF receptor prevented hepatocyte death in hepatocyte-specific *Tak1*-deleted (*Tak1 Δ Hep*) mice, indicating that TNF receptor signaling is responsible for spontaneous liver injury and inflammation in *Tak1 Δ Hep* mice.³

TGF- β signaling activates Smad-dependent canonical and Smad-independent noncanonical TAK1-mediated signal pathways that activate JNK and p38.^{8–10} TGF- β signaling regulates cell apoptosis, proliferation, differentiation, and extracellular matrix production. The importance of TGF- β signaling in cancer development has been demonstrated in several types of human cancers, including colon cancer, prostate cancer, and breast cancer.¹¹ In HCC, the functions of TGF- β signaling are paradoxical. In human HCC, persistent up-regulation of TGF- β was observed, and several reports indicate TGF- β signaling functions as a tumor suppressor. Alternatively, TGF- β signaling promotes the growth and migration of HCC through the induction of connective tissue growth factor (CTGF).^{9,12,13} It is unclear whether TGF- β signaling promotes or suppresses HCC development in *Tak1 Δ Hep* mice. In the present study, we investigated the role of TGF- β signaling in hepatocyte death, liver inflammation, fibrosis, and HCC spontaneously developed in *Tak1 Δ Hep* mice. We found that TGF- β signaling promoted HCC development through induction of hepatocyte death and its subsequent compensatory proliferation in early phase. Importantly, in HCC of *Tak1 Δ Hep* mice, TGF- β signaling is associated with overexpression of anti-apoptotic Bcl-xL, procarcinogenic β -catenin, and CTGF, which prevent tumor apoptosis and promote cancer growth. In addition, TGF- β signaling also contributes to angiogenesis through vascular endothelial growth factor (VEGF) expression to promote HCC growth in *Tak1 Δ Hep* mice.

Materials and Methods

Mouse Colonies

Albumin-Cre recombinase transgenic mice (Alb-Cre Tg mice), TGF- β receptor-2 (*Tgfb β 2*^{flox/flox} mice), and *Smad4*^{flox/flox} mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mice carrying the floxed allele of *Tak1* (*Tak1*^{flox/flox} mice) have been described previously.³ These mouse lines were crossed to generate the following types of mice with genes specifically deleted in hepatocytes: Alb-cre/+ *Tak1*^{flox/flox} mice (*Tak1* ^{Δ Hep}), Alb-Cre/+ *Tgfb β 2*^{flox/flox} mice (*Tgfb β 2* ^{Δ Hep}), Alb-cre/+ *Tak1*^{flox/flox} *Tgfb β 2*^{flox/flox} (*Tak1*/*Tgfb β 2* ^{Δ Hep}), and Alb-cre/+ *Tak1*^{flox/flox} *Smad4*^{flox/flox} (*Tak1*/*Smad4* ^{Δ Hep}) mice on C57BL6 background. Both males and females were used in the study and Cre-negative animals were used as WT controls. In our previous report, we demonstrated that *Tak1* ^{Δ Hep} mice spontaneously develop liver injury, inflammation, fibrosis, and tumors without sex disparity.^{3,4} One-month-old mice were used for assessing spontaneous liver injury, inflammation, and fibrosis, and 9-month-old mice were used for examining spontaneous liver fibrosis and HCC. In some experiments (Figure 7E), HCC was induced chemically via intraperitoneal injection of 25 mg/kg *N*-nitrosodiethylamine (DEN) (Sigma-Aldrich, St Louis, MO) into 14-day-old male *Tgfb β 2*^{flox/flox} and *Tgfb β 2* ^{Δ Hep} mice.¹⁴ Nine months after DEN injection, the chemically induced HCC was evaluated. All mice received humane care according to the National Institutes of Health recommendations outlined in their Guide for the Care and Use of Laboratory Animals. All animal experiments were approved by the University of California San Diego Institutional Animal Care and Use Committee.

Human Liver and HCC Samples

Paraffin-embedded human liver tissues were acquired from liver biopsy samples of patients with chronic hepatitis C and from explanted or surgically resected livers of patients with HCC. All patients provided written informed consent, and the study was approved by the University of California San Diego Institutional Review Board.

Other Materials and Methods

Other materials and methods for mouse tissue processing, histologic examination, Western blot analysis, quantitative real-time polymerase chain reaction, cell isolation, and treatment are described in the Supplementary Materials and Methods.

Statistical Analysis

Differences between 2 groups were compared using the Mann-Whitney *U* test or 2-tailed unpaired Student *t* test. Differences between multiple groups were compared using 1-way analysis of variance using SPSS software (SPSS Inc, Chicago, IL). *P* values < .05 were considered significant.

Results

Expression of TGF- β Signaling Components in Tumors From *Tak1* ^{Δ Hep} Mice

As reported previously, *Tak1* ^{Δ Hep} mice develop spontaneous liver inflammation, fibrosis, and HCC without treatment with carcinogens.³ In contrast, their WT counterparts did not develop liver tumors and fibrosis, even at 12 months of age.³ We initially investigated the expressions of TGF- β signaling components in liver tumors of 9-month-old *Tak1* ^{Δ Hep} mice. An immunohistochemical study demonstrated that expressions of TGF- β R type 2 and phosphorylated Smad2/3 were modestly increased in nontumor livers of *Tak1* ^{Δ Hep} mice and remarkably increased in HCC lesions of *Tak1* ^{Δ Hep} mice in comparisons with WT normal livers (Figure 1A). Immunoblots showed dramatically increased phosphorylation and

nuclear translocation of Smad2/3, as well as blunted expression of TAK1 protein in tumors of *Tak1^{ΔHep}* mice (Figure 1B). Expressions of genes related to TGF- β signaling, including *Tgfb1*, *Tgfb2*, and *Tgfb1*, were also increased in tumors of *Tak1^{ΔHep}* mice (Figure 1C). These results suggest that activation of TGF- β signaling is associated with spontaneous HCC development in *Tak1^{ΔHep}* mice.

Ablation of *Tgfb2* Prevents Spontaneous HCC Development in *Tak1^{ΔHep}* Mice

To investigate the contribution of TGF- β signaling in spontaneous hepatocarcinogenesis in *Tak1^{ΔHep}* mice, we generated *Tak1/Tgfb2^{ΔHep}* mice by crossing *Tak1^{ΔHep}* mice with *Tgfb2^{ΔHep}* mice. Deletion of hepatic TAK1 and/or TGF β R2 protein in *Tak1^{ΔHep}*, *Tgfb2^{ΔHep}*, or *Tak1/Tgfb2^{ΔHep}* mice was confirmed by immunoblotting (Figure 1D). In the liver from 1-month-old *Tak1^{ΔHep}* mice, Smad2 and Smad3 were strongly phosphorylated, however, such signaling was diminished by *Tgfb2* deletion (Figure 1D). This demonstrates that the deletion of *Tgfb2* blocks TGF- β signaling in *Tak1^{ΔHep}* mice. *Tak1^{flox/flox}* mice and *Tgfb2^{ΔHep}* mice were used as corresponding WT controls, and these mice showed no appearances of spontaneous liver tumors, even at 12 months of age. *Tak1^{ΔHep}* mice developed spontaneous HCC at 9 months of age; in comparisons, *Tak1/Tgfb2^{ΔHep}* mice developed tumors significantly lower in multiplicity and maximal size of tumors (Figure 1D–F). These results indicate that TGF- β signaling is responsible for spontaneous HCC development in *Tak1^{ΔHep}* mice. Additionally, we confirmed no significant sex disparity in HCC formation in both *Tak1^{ΔHep}* mice and *Tak1/Tgfb2^{ΔHep}* mice (Supplementary Figure 1).

TGF- β Signaling Is Required for Spontaneous Liver Injury and Inflammation in *Tak1^{ΔHep}* Mice

Next, we investigated whether TGF- β signaling contributes to spontaneous liver injury and inflammation in *Tak1^{ΔHep}* mice. Histologic analysis showed evident hepatocyte death and inflammatory cell infiltration to have occurred in both 1- and 9-month-old *Tak1^{ΔHep}* mice (Figure 2A). These phenotypes were abolished in the livers of *Tak1/Tgfb2^{ΔHep}* mice (Figure 2A). Elevation of serum alanine aminotransferase (ALT) levels in *Tak1^{ΔHep}* mice were also suppressed by *Tgfb2* deletion (Figure 2B). Kupffer cells/macrophages are the major source of inflammatory cytokines produced in response to hepatocyte damage.^{15,16} According to the immunohistochemical staining of F4/80 in 1-month-old mice, the number of infiltrated hepatic macrophages in *Tak1^{ΔHep}* mice was significantly lowered in *Tak1/Tgfb2^{ΔHep}* mice (Figure 2C and D). Accordingly, *Tak1/Tgfb2^{ΔHep}* livers had attenuated expression of inflammatory genes, including TNF α , IL-6, CCL2, and IL-1 β compared with *Tak1^{ΔHep}* livers (Figure 2E). These results indicate that spontaneous liver injury and inflammation in *Tak1^{ΔHep}* mice are associated with TGF- β -mediated hepatocyte damage, which drives Kupffer cell/macrophage activation and production of inflammatory cytokines.

TGF- β Signaling in Hepatocytes Drives Spontaneous Liver Fibrosis in *Tak1^{ΔHep}* Mice

Subsequently, we investigated the role of hepatocyte's TGF- β signaling in the development of liver fibrosis in *Tak1^{ΔHep}* mice. Spontaneous liver fibrosis in *Tak1^{ΔHep}* mice was significantly inhibited by the additional deletion of *Tgfb2* (Figure 3A and B). The number of activated hepatic stellate cells that express α -smooth muscle actin was also decreased in *Tak1/Tgfb2^{ΔHep}* mice (Figure 3C and D). Expressions of fibrogenic genes, such as *Col1a1*, *Acta2*, *Timp1*, and *Tgfb1* were significantly reduced in *Tak1/Tgfb2^{ΔHep}* mice compared with the *Tak1^{ΔHep}* mice (Figure 3E). These findings demonstrate that TGF- β signaling in hepatocytes is required for the development of spontaneous liver fibrosis in *Tak1^{ΔHep}* mice.

TGF- β Signaling Is Associated With Spontaneous Hepatocyte Apoptosis and Compensatory Proliferation in *Tak1* ^{Δ Hep} Mice

Hepatocyte death and compensatory proliferation are key drivers for the initiation of HCC after exposure to carcinogen or chronic liver inflammation.^{17,18} According to the elevated serum ALT levels caused by the deletion of hepatocyte's *Tak1* (Figure 2B), spontaneous hepatocyte apoptosis was remarkably increased in *Tak1* ^{Δ Hep} mice, which was suppressed in *Tak1/Tgfb β 2* ^{Δ Hep} mice (Figure 4A and B). Decreased hepatocyte apoptosis in *Tak1/Tgfb β 2* ^{Δ Hep} mice was also demonstrated by the lack of cleaved caspase 3 induction (Figure 4E). The increased pro-apoptotic gene, *Bax*, in *Tak1* ^{Δ Hep} livers was decreased in *Tak1/Tgfb β 2* ^{Δ Hep} livers, as measured by quantitative real-time polymerase chain reaction (Figure 4D). Because the compensatory hepatocyte proliferation in response to massive liver cell death is associated with spontaneous hepatocarcinogenesis in *Tak1* ^{Δ Hep} mice,³ we investigated the regenerative responses of *Tak1/Tgfb β 2* ^{Δ Hep} mice. Cyclin D1 expression and proliferation cell nuclear antigen–positive cells were increased in *Tak1* ^{Δ Hep} mice, but not in *Tak1/Tgfb β 2* ^{Δ Hep} mice (Figure 4A, C, and E). These findings demonstrated that the loss of TGF- β receptor signaling in hepatocytes inhibits spontaneous hepatocyte death and its subsequent proliferation in *Tak1* ^{Δ Hep} mice.

TAK1-NF- κ B Axis Protects Hepatocytes From Apoptosis Induced by TGF- β

We investigated whether TGF- β signaling participates in hepatocyte death under *Tak1*-deficient condition using primary culture hepatocytes. WT hepatocytes did not undergo apoptosis with or without TGF- β treatment. *Tak1* deficiency induced modest hepatocyte apoptosis, and TGF- β challenge dramatically increased apoptosis in *Tak1* ^{$-/-$} hepatocytes (Figure 5A). Consistently, TGF- β treatment induced cleavage of caspase 3 in *Tak1* ^{$-/-$} hepatocytes, but not in WT hepatocytes (Figure 5B). WT hepatocytes displayed phosphorylation of JNK and p38 induced by TGF- β treatment, but *Tak1* ^{$-/-$} hepatocytes did not. Interestingly, the signal intensity of phosphorylation of Smad2 and Smad3 was stronger in *Tak1* ^{$-/-$} hepatocytes than in WT hepatocytes (Figure 5B), suggesting that the TAK1-dependent pathway negatively regulates Smad2/3 activation and cell death signaling. To determine whether TGF- β signaling regulates NF- κ B activation, hepatocytes isolated from NF- κ B–green fluorescent protein (GFP) reporter mice were used. When the WT hepatocytes were challenged with TGF- β , GFP reporter expression increased. In contrast, this was not observed in the hepatocytes isolated from *Tak1* ^{$-/-$} NF- κ B-GFP reporter mice (Figure 5C and D). To test whether NF- κ B-mediated survival signaling prevents TGF- β -mediated hepatocyte apoptosis, NF- κ B activation was blocked via infection with adenoviral vector expressing I κ B super-repressor, a potent inhibitor of NF- κ B. Upon inhibition of NF- κ B, TGF- β treatment induced hepatocyte apoptosis (Figure 5E). Deletion of *Tak1* abolishes TGF- β -mediated NF- κ B activation and thereby increases susceptibility to TGF- β -mediated hepatocyte apoptosis.

Smad Signaling Is Required for TGF- β -Mediated Apoptosis in *Tak1* ^{$-/-$} Hepatocytes

As shown in Figures 1D and 5B, Smad2 and Smad3 were overactivated in *Tak1* ^{$-/-$} livers and in *Tak1* ^{$-/-$} hepatocytes treated with TGF- β . This led us to investigate whether Smad activation contributes to TGF- β -mediated hepatocyte apoptosis. To inactivate Smad signaling in *Tak1* ^{$-/-$} hepatocytes, we used primary hepatocytes isolated from *Tak1/Smad4* ^{Δ Hep} mice. Although TGF- β treatment increased the number of apoptosis in both *Tak1* ^{$-/-$} and *Tak1/Smad4* double-knockout hepatocytes in comparison with the nontreatment group, apoptosis was suppressed in *Tak1/Smad4* double-knockout hepatocytes compared with *Tak1* ^{$-/-$} hepatocytes (Figure 6A), indicating that Smad activation is required for the induction of apoptosis in *Tak1* ^{$-/-$} hepatocytes mediated by TGF- β . We further confirmed the requirement of Smad pathways by silencing *Smad2* using small interfering

RNA in primary hepatocytes; TGF- β -induced apoptosis in *Tak1*^{-/-} hepatocytes was suppressed in *Smad2*-silenced hepatocytes (Supplementary Figure 2).

We then investigated the in vivo roles of Smad pathway for the liver pathology in *Tak1* ^{Δ Hep} mice by using *Tak1/Smad4* ^{Δ Hep} mice. Spontaneous hepatocytes apoptosis was increased in 1-month-old *Tak1* ^{Δ Hep} mice, which was suppressed in *Tak1/Smad4* ^{Δ Hep} mice as assessed by counting the number of apoptotic terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)-positive hepatocytes (Figure 6B). Consistent with the results from TUNEL staining, serum ALT levels in *Tak1/Smad4* ^{Δ Hep} mice were significantly lower than those in *Tak1* ^{Δ Hep} mice (Figure 6C). Expression of inflammatory and fibrogenic genes, as well as fibrillar collagen deposition, were significantly suppressed by *Smad4* deletion in 1-month-old *Tak1* ^{Δ Hep} mice (Figure 6D, E). Notably, HCC formation in *Tak1/Smad4* ^{Δ Hep} mice was significantly reduced compared with *Tak1* ^{Δ Hep} mice at 9 months of age (Figure 6F). These results indicate that Smad activation in hepatocytes is crucial for spontaneous liver injury, inflammation, fibrosis, and tumorigenesis in *Tak1* ^{Δ Hep} mice.

Anti-Apoptotic and Pro-Oncogenic Gene Expression and Angiogenesis in HCC From *Tak1* ^{Δ Hep} Mice are TGF- β Signaling-Dependent

To explore additional TGF- β -dependent mechanisms that drive hepatocarcinogenesis, we further analyzed HCC tissues in 9-month-old *Tak1* ^{Δ Hep} mice. We investigated pro-oncogene and anti-apoptotic gene expression in HCC from *Tak1* ^{Δ Hep} mice. Although expressions of pro-oncogenes, such as *Ctnnb1*, *Yap1*, and *Wisp1*, were significantly increased in tumors from *Tak1* ^{Δ Hep} mice, these expressions were decreased in tumors from *Tak1/Tgfb2* ^{Δ Hep} mice (Figure 7A). Expression of anti-apoptotic Bcl-2 was not affected in the tumors from *Tak1* ^{Δ Hep} or *Tak1/Tgfb2* ^{Δ Hep} mice. Notably, anti-apoptotic Bcl-xL increased significantly, and pro-apoptotic Bax decreased in the tumors from *Tak1* ^{Δ Hep} mice compared with WT normal livers and nontumor liver tissues from *Tak1* ^{Δ Hep} mice; however, these changes were not seen in *Tak1/Tgfb2* ^{Δ Hep} mice (Figure 7B). Because CTGF is known to promote growth and migration of HCC, *Ctgf* messenger RNA expression was assessed.^{9,12,13,19} Although tumors from *Tak1* ^{Δ Hep} mice exhibited increased *Ctgf* messenger RNA expression compared with nontumor tissues, tumors from *Tak1/Tgfb2* ^{Δ Hep} mice did not (Figure 7C). Due to the pivotal role of angiogenesis in the pathogenesis of HCC, we examined the expression of VEGFa, a potent proangiogenic factor, and its receptor, VEGFR2, in the tumors of *Tak1* ^{Δ Hep} mice and *Tak1/Tgfb2* ^{Δ Hep} mice. VEGFa was overexpressed in tumors from *Tak1* ^{Δ Hep} mice, but not from *Tak1/Tgfb2* ^{Δ Hep} mice (Figure 7D). VEGFR2-expressing endothelial cells were also increased in tumors from *Tak1* ^{Δ Hep} mice compared with tumors from *Tak1/Tgfb2* ^{Δ Hep} mice (Figure 7D). These results suggest that expression of Bcl-xL, CTGF, and VEGF-mediated angiogenesis are TGF- β -dependent in the development of HCC in *Tak1* ^{Δ Hep} mice.

TGF- β Signaling in a Mouse Model for Chemically Induced HCC and in Human HCC

To examine whether TGF- β signaling is a general promoter for HCC growth in vivo, we assessed DEN-induced HCC mouse model in WT mice and *Tgfb2* ^{Δ Hep} mice. Neonatal DEN treatment induced multiple, large-sized HCC in WT mice at 9 months after DEN injection. In contrast, inactivation of TGF- β signaling by deletion of *Tgfb2* reduced HCC formation induced by DEN (Figure 7E). Consistently, serum ALT levels were higher in WT mice than in *Tgfb2* ^{Δ Hep} mice after DEN treatment (Supplementary Figure 3). Analogous in pattern to HCC from *Tak1* ^{Δ Hep} and *Tgfb2* ^{Δ Hep} mice, HCC from DEN-treated WT mice had increased expressions of prooncogenes (*Ctnnb1*, *Yap1*, and *Wisp1*), *Bcl-xl*, and *Ctgf*, and these expressions were suppressed in HCC from *Tgfb2* ^{Δ Hep} mice treated with DEN (Supplementary Figure 4A–D). VEGFa expression and angiogenesis were increased in

DEN-induced HCC from WT mice, but not in HCC from *Tgfr2^{ΔHep}* mice (Supplementary Figure 4E). These results indicate that TGF- β is a promoter for DEN-induced HCC. Finally, we assessed activation of TGF- β signaling by comparing liver biopsy specimens of patients with chronic hepatitis C with hepatic fibrosis (hepatitis C virus–non-HCC controls) with patients with chronic hepatitis C infection and HCC (hepatitis C virus–HCC cases) with immunohistochemistry for phosphorylation of Smad2/3. In liver tissues from patients with chronic hepatitis C–induced fibrosis, phosphorylation of Smad2/3 was seen only in nonparenchymal cells and not in liver parenchymal cells. As we predicted, in patients with chronic hepatitis C and HCC, we found increased phosphorylation and nuclear translocation of Smad2/3 (Figure 7F), providing clinical relevance of activation of TGF- β signaling in human HCC.

Discussion

TAK1 is a mitogen-activated protein kinase kinase kinase that is activated in the signaling cascade of IL-1 β , Toll-like receptors, TNF, and TGF- β . TAK1 requires binding to TAB2 and TAB3 for activation of the downstream kinases JNK, p38, and IKK.^{5,6} These kinases further activate transcription factors AP-1 and NF- κ B. The IKK–NF- κ B pathway is anti-apoptotic and anti-oncogenic, whereas the JNK signaling is pro-apoptotic and pro-carcinogenic.⁷ Because TAK1 regulates both IKK–NF- κ B and JNK pathways, the functions of TAK1 in hepatocyte death and carcinogenesis were uncertain. We and others have developed a genetically engineered mouse model that specifically knocked out *Tak1* gene in the liver.^{3,4} These mice spontaneously develop HCC accompanied by liver inflammation and fibrosis, which best mimics the progression of human HCC; therefore, *Tak1^{ΔHep}* mice serve as an excellent mouse model to analyze the mechanisms of hepatocarcinogenesis, especially for the link between inflammation, fibrosis, and carcinogenesis.

TGF- β signaling regulates cell proliferation, apoptosis, migration, angiogenesis, immunity, fibrosis, and cancer development.^{8,10,20} TGF- β binds to the receptor subunit TGF- β receptor 2, and then activates TGF- β receptor 1. Intracellular domain of TGF- β receptor 1 phosphorylates Smad2 and Smad3, and forms a complex with Smad4 that translocates into the nucleus to regulate gene transcription. TGF- β signaling also activates the Smad-independent, TAK1-dependent pathway that activates JNK and p38.^{8,20} In *Tak1^{ΔHep}* mice, increased production of TGF- β and overactivation of Smad2 and Smad3 were observed, indicating that the TGF- β receptor signaling is activated in *Tak1^{ΔHep}* livers. Due to the lack of TAK1, TGF- β -induced JNK and p38 phosphorylation were impaired. We demonstrate that TGF- β stimulation induced NF- κ B activation in WT hepatocytes, and inhibition of NF- κ B in TGF- β -stimulated hepatocytes caused hepatocyte apoptosis (Figure 5C and E). In contrast, induction in hepatic apoptosis was not seen with inhibition of JNK or p38 in TGF- β -stimulated hepatocytes (Supplementary Figure 5). Because *Tak1^{-/-}* hepatocytes are more susceptible to TGF- β -mediated cell death, the TAK1–NF- κ B pathway is an essential survival signal in the TGF- β signaling. *Tak1^{-/-}* deficiency augmented TGF- β -mediated Smad2/3 phosphorylation. This suggests that the TAK1–NF- κ B pathway can negatively regulate Smad2/3 activation, and overactivation of Smad2/3 is associated with TGF- β -mediated cell death in *Tak1^{-/-}* hepatocytes. In fact, inactivation of Smad pathway attenuated TGF- β -mediated cell death in *Tak1^{-/-}* hepatocytes (Figure 6A, Supplementary Figure 2). The importance of Smad signaling in TGF- β -mediated hepatocyte apoptosis was also confirmed by decreased hepatocyte apoptosis in *Tak1/Smad4^{ΔHep}* mice (Figure 6B).

To determine the role of TGF- β –Smad signaling in hepatocytes for the regulation of spontaneous liver inflammation, fibrosis, and carcinogenesis in *Tak1^{ΔHep}* mice, we have generated hepatocyte-specific *Tak1* and *Tgfr2* double-knockout (*Tak1/Tgfr2^{ΔHep}*) mice, and *Tak1/Smad4^{ΔHep}* mice. The additional deletion of hepatocyte's TGF- β –Smad signaling

in *Tak1^{ΔHep}* mice resulted in decreased spontaneous carcinogenesis, fibrosis, inflammation, and hepatocyte apoptosis. This implicates that TGF- β -Smad signaling in hepatocytes promotes liver fibrosis and formation of liver tumors that spontaneously develop in the setting of TAK1 inactivation (Figures 1–4). Notably, the suppression of liver pathology in *Tak1/Smad4^{ΔHep}* mice was less than that in *Tak1/Tgfb2^{ΔHep}* mice. This suggests that, in addition to Smad, TGF- β -mediated unknown pathways, such as phosphatidylinositol 3 kinase or RhoA/ROCK pathway, are involved in TGF- β -mediated liver phenotype in *Tak1^{ΔHep}* mice.

Because spontaneous hepatocyte death and carcinogenesis in *Tak1^{ΔHep}* mice were reduced in *Tak1/Tgfb2^{ΔHep}* and *Tak1/Smad4^{ΔHep}* mice, we concluded that TGF- β -Smad-mediated hepatocyte injury and compensatory proliferation of the surviving hepatocytes are the probable cause of spontaneous HCC development in *Tak1^{ΔHep}* mice. Particularly, HCC from 9-month-old *Tak1^{ΔHep}* mice overexpressed anti-apoptotic Bcl-xL, but not HCC from *Tak1/Tgfb2^{ΔHep}* mice. This suggests that hepatocytes lacking *Tak1* become resistance to TGF- β -mediated apoptosis when they transform to HCC. We also characterized the oncogenic properties of HCC developed in *Tak1^{ΔHep}* mice; the HCC of *Tak1^{ΔHep}* mice highly expressed pro-oncogene β -catenin (Figure 7). Yes-associated protein has been identified as an oncoprotein that is regulated by the Hippo signaling pathway.²¹ Yes-associated protein is overexpressed in lung, ovarian, colon, prostate, and liver cancer, and is associated with the prognosis for HCC patients.^{22–24} Our data demonstrated that Yes-associated protein 1 is highly expressed in HCC from *Tak1^{ΔHep}* mice (Figure 7). Wnt signaling downstream target, WISP1, is a member of the CTGF family, and is associated with HCC development.²⁵ Although WISP1 expression was very high in tumors from *Tak1^{ΔHep}* mice, expression of this oncogene was significantly suppressed in tumors from *Tak1/Tgfb2^{ΔHep}* mice, suggesting that TGF- β signaling regulates WISP1 expression in HCC. TGF- β signaling induces CTGF production in hepatocytes, which is associated with fibrosis, and HCC growth, and migration.^{19,26} Hepatocytes and HCC of *Tak1^{ΔHep}* mice express CTGF through TGF- β signaling. It is postulated that, in combination with TGF- β , CTGF promotes HCC growth and liver fibrosis in *Tak1^{ΔHep}* mice. Consistent with previous reports,^{27,28} TGF- β induced production of VEGF in hepatocytes that augmented angiogenesis in tumors and assisted tumor growth in *Tak1^{ΔHep}* mice.

There exist a number of studies demonstrating that TGF- β signaling is a tumor suppressor.⁹ Human gastric, colon, and pancreatic cancer express mutant forms of TGF- β signaling components that inhibit activity of TGF- β signaling.²⁹ Mice with inactivation of TGF β R2 by the ectopic expression of soluble TGF β R2, or haploinsufficiency for *Tgfb2* or *elf*, a signaling molecule essential for TGF- β signaling, augmented HCC development.^{12,13,30} Tumor suppressive effect of TGF- β signaling can be mediated by increasing tumor-suppressing genes (eg, p15, p21) and inducing apoptosis of cancer cells.⁹ In contrast, sustained elevation of TGF- β is considered to promote malignancies and metastases in glioma cells and breast cancer.^{31–33} TGF- β signaling induces cell migration of HCC cells through induction of epithelial to mesenchymal transition, and expressions of anti-apoptotic genes and CTGF to promote HCC growth.^{19,34,35} Interestingly, additional deletion of *Tgfb2* in *p53^{ΔHep}* mice inhibits spontaneous development of HCC.³⁶ A recent publication demonstrated that TGF- β signaling is required for liver progenitor cell-associated hepatocarcinogenesis, which corroborates our results.³⁷ These findings serve as additional evidence that TGF- β signaling promotes HCC formation in vivo. To address whether TGF- β signaling promotes HCC only in the specific genetic conditions, we provided additional evidence that *Tgfb2* ablation in hepatocytes inhibits chemically induced HCC (Figure 7E). In addition to previous reports,^{38–41} our data demonstrated that TGF- β signaling is activated in human HCC as increased phosphorylation and nuclear translocation of Smad2/3 (Figure 7F), which provided evidence in the activation of TGF- β signaling in human HCC.

It is postulated that function of TGF- β signaling as a tumor promoter or a tumor suppressor is dependent on cell types, tissues, organs, and stage of cancer. Our data clearly demonstrate that TGF- β signaling in hepatocytes contributes to tumor promotion.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding This study is supported by National Institutes of Health grant R01AA02172 (ES), R01DK085252 (ES), P42ES010337 (Project5, ES), and the pilot grant from the University of California San Diego Digestive Diseases Research Development Center (DK080506) (ES). Dr Loomba is supported in part by the American Gastroenterological Association (AGA) Foundation–Sucampo–ASP Designated Research Award in Geriatric Gastroenterology and by a T. Franklin Williams Scholarship Award. Funding provided by Atlantic Philanthropies, Inc., the John A. Hartford Foundation, the Association of Specialty Professors, and the AGA and grant K23-DK090303-2 and P30CA23100-27.

Abbreviations used in this paper

ALT	alanine aminotransferase
CTGF	connective tissue growth factor
DEN	N-nitrosodiethylamine
GFP	green fluorescent protein
HCC	hepatocellular carcinoma
IKK	I κ B kinase
IL	interleukin
JNK	c-Jun-N-terminal kinase
NF-κB	nuclear factor- κ B
TAK1	TGF- β -activated kinase 1
<i>Tak1</i>^{ΔHep} mice	hepatocyte-specific <i>Tak1</i> -deleted mice
TGF	transforming growth factor
Tgfr2	TGF- β receptor-2
TNF	tumor necrosis factor
TUNEL	terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling
VEGF	vascular endothelial growth factor
WT	wild-type

References

1. Weber A, Boege Y, Reisinger F, et al. Chronic liver inflammation and hepatocellular carcinoma: persistence matters. *Swiss Med Wkly.* 2011; 141:w13197. [PubMed: 21557112]
2. Karin M. Nuclear factor-kappaB in cancer development and progression. *Nature.* 2006; 441:431–436. [PubMed: 16724054]
3. Inokuchi S, Aoyama T, Miura K, et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. *Proc Natl Acad Sci U S A.* 2010; 107:844–849. [PubMed: 20080763]

4. Bettermann K, Vucur M, Haybaeck J, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. *Cancer Cell*. 2010; 17:481–496. [PubMed: 20478530]
5. Landstrom M. The TAK1-TRAF6 signalling pathway. *Int J Biochem Cell Biol*. 2010; 42:585–589. [PubMed: 20060931]
6. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. *Trends Pharmacol Sci*. 2012; 33:522–530. [PubMed: 22795313]
7. Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. *Gastroenterology*. 2012; 143:307–320. [PubMed: 22705006]
8. Massague J. TGFbeta in cancer. *Cell*. 2008; 134:215–230. [PubMed: 18662538]
9. Majumdar A, Curley SA, Wu X, et al. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. 2012; 9:530–538. [PubMed: 22710573]
10. Dooley S, ten Dijke P. TGF-beta in progression of liver disease. *Cell Tissue Res*. 2012; 347:245–256. [PubMed: 22006249]
11. Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. *Cell*. 2008; 133:66–77. [PubMed: 18394990]
12. Im YH, Kim HT, Kim IY, et al. Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. *Cancer Res*. 2001; 61:6665–6668. [PubMed: 11559531]
13. Kanzler S, Meyer E, Lohse AW, et al. Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. *Oncogene*. 2001; 20:5015–5024. [PubMed: 11526486]
14. Maeda S, Kamata H, Luo JL, et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. *Cell*. 2005; 121:977–990. [PubMed: 15989949]
15. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science*. 2007; 317:121–124. [PubMed: 17615358]
16. Sakurai T, He G, Matsuzawa A, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. *Cancer Cell*. 2008; 14:156–165. [PubMed: 18691550]
17. Qiu W, Wang X, Leibowitz B, et al. PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. *Hepatology*. 2011; 54:1249–1258. [PubMed: 21725994]
18. He G, Karin M. NF-kappaB and STAT3—key players in liver inflammation and cancer. *Cell Res*. 2011; 21:159–68. [PubMed: 21187858]
19. Mazzocca A, Fransvea E, Dituri F, et al. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. *Hepatology*. 2010; 51:523–534. [PubMed: 19821534]
20. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. *Nat Genet*. 2001; 29:117–129. [PubMed: 11586292]
21. Liu AM, Xu MZ, Chen J, et al. Targeting YAP and Hippo signaling pathway in liver cancer. *Expert Opin Ther Targets*. 2010; 14:855–868. [PubMed: 20545481]
22. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in *Drosophila* and mammals. *Cell*. 2007; 130:1120–1133. [PubMed: 17889654]
23. Steinhardt AA, Gayyed MF, Klein AP, et al. Expression of Yes-associated protein in common solid tumors. *Hum Pathol*. 2008; 39:1582–1589. [PubMed: 18703216]
24. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. *Cancer*. 2009; 115:4576–4585. [PubMed: 19551889]
25. Cervello M, Giannitrapani L, Labbozzetta M, et al. Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. *Ann N Y Acad Sci*. 2004; 1028:432–439. [PubMed: 15650268]
26. Kodama T, Takehara T, Hikita H, et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. *J Clin Invest*. 2011; 121:3343–3356. [PubMed: 21747166]

27. Benckert C, Jonas S, Cramer T, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. *Cancer Res.* 2003; 63:1083–1092. [PubMed: 12615726]
28. Sugano Y, Matsuzaki K, Tahashi Y, et al. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. *Oncogene.* 2003; 22:2309–2321. [PubMed: 12700666]
29. Achyut BR, Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. *Gastroenterology.* 2011; 141:1167–1178. [PubMed: 21839702]
30. Kitisin K, Ganesan N, Tang Y, et al. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. *Oncogene.* 2007; 26:7103–7110. [PubMed: 17546056]
31. Bruna A, Darken RS, Rojo F, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. *Cancer Cell.* 2007; 11:147–160. [PubMed: 17292826]
32. Arteaga CL. Inhibition of TGFbeta signaling in cancer therapy. *Curr Opin Genet Dev.* 2006; 16:30–37. [PubMed: 16377175]
33. Padua D, Massague J. Roles of TGFbeta in metastasis. *Cell Res.* 2009; 19:89–102. [PubMed: 19050696]
34. Xu Z, Shen MX, Ma DZ, et al. TGF-beta1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells. *Cell Res.* 2003; 13:343–350. [PubMed: 14672557]
35. Caja L, Bertran E, Campbell J, et al. The transforming growth factor-beta (TGF-beta) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. *J Cell Physiol.* 2011; 226:1214–1223. [PubMed: 20945437]
36. Morris SM, Baek JY, Koszarek A, et al. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. *Hepatology.* 2012; 55:121–131. [PubMed: 21898503]
37. Wu K, Ding J, Chen C, et al. Hepatic TGF-beta gives rise to tumor-initiating cells and promotes liver cancer development. *Hepatology.* 2012; 56:2255–2267. [PubMed: 22898879]
38. Ji GZ, Wang XH, Miao L, et al. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma. *World J Gastroenterol.* 2006; 12:644–648. [PubMed: 16489684]
39. Fransvea E, Mazzocca A, Antonaci S, et al. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. *Hepatology.* 2009; 49:839–850. [PubMed: 19115199]
40. Matsuzaki K, Date M, Furukawa F, et al. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. *Cancer Res.* 2000; 60:1394–1402. [PubMed: 10728705]
41. Lee D, Chung YH, Kim JA, et al. Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma. *Oncology.* 2012; 82:11–18. [PubMed: 22269311]

Figure 1.

TGF- β signaling is required for spontaneous hepatocarcinogenesis in *Tak1^{ΔHep}* mice. (A) Immunohistochemistry for TGF β R2 and phosphorylated Smad2/3 in liver tissues from 9-month-old WT, and nontumor livers and tumors from 9-month-old *Tak1^{ΔHep}* mice is shown. Original magnification $\times 200$ for TGF β R2 staining and $400\times$ for Smad2/3 staining. (B) Western blotting for phosphorylated Smad2 and Smad3 and TAK1 in liver tissues from 9-month-old WT, and nontumor liver tissues and tumors from 9-month-old *Tak1^{ΔHep}* mice. β -actin was used as a loading control. (C) Expression of *Tgfb1*, *Tgfb2*, and *Tgfb1* messenger RNA in liver tissues from 9-month-old WT, and nontumor liver tissues and tumors from 9-month-old *Tak1^{ΔHep}* mice was measured by quantitative real-time polymerase chain reaction. NT, nontumor liver, T, tumors. (n=6, each samples) (D, left) Immunoblots for TAK1, TGF β R2, phospho-Smad2, phospho-Smad3, Smad4 in the livers of WT, *Tak1^{ΔHep}*, *Tak1/Tgfb2^{ΔHep}*, and *Tgfb2^{ΔHep}* mice at 1 month of age are shown. β -actin was used as a loading control. (D, right) Representative macroscopic pictures of livers of 9-month-old WT, *Tak1^{ΔHep}*, *Tak1/Tgfb2^{ΔHep}*, and *Tgfb2^{ΔHep}* mice. (E) The number of tumors per mouse was counted and the maximum diameter of individual tumor nodules was measured (WT, n = 10; *Tak1^{ΔHep}*, n = 29; *Tak1/Tgfb2^{ΔHep}*, n = 27; *Tgfb2^{ΔHep}*, n = 10). (F) H&E staining. Data are represented as mean $\pm$ standard error of mean. * $P < .05$; ** $P < .01$.

Figure 2.

Ablation of *Tgfb2* in *Tak1^{ΔHep}* mice reduces spontaneous liver inflammation. (A) H&E staining in the livers of 1- and 9-month-old WT, *Tak1^{ΔHep}*, *Tak1/Tgfb2^{ΔHep}*, and *Tgfb2^{ΔHep}* mice. Original magnification 200×. (B) Serum ALT levels were measured in WT, *Tak1^{ΔHep}*, *Tak1/Tgfb2^{ΔHep}*, and *Tgfb2^{ΔHep}* mice at age 1, 4, and 9 months (n = 8 at the each time point). (C, D) Immunohistochemistry for F4/80 in WT, *Tak1^{ΔHep}*, *Tak1/Tgfb2^{ΔHep}*, and *Tgfb2^{ΔHep}* mice at 1 month of age. Quantification (C) and representative pictures (D). Original magnification 200×. (E) Hepatic messenger RNA expression of inflammatory genes (*Tnf*, *Il6*, *Ccl2*, and *Il1b*) in mice at the age of 1 month was determined by quantitative real-time polymerase chain reaction. Data are represented as mean ± standard error of mean. **P* < .05; ***P* < .01.

Figure 3.

Loss of *Tgfb2* in *Tak1^{ΔHep}* mice suppresses spontaneous liver fibrosis. (A, B) WT, *Tak1^{ΔHep}*, *Tak1/Tgfb2^{ΔHep}*, and *Tgfb2^{ΔHep}* mice at the age of 1, 4, and 9 months ($n = 7$ at the each time point) were used for analysis. Fibrillar collagen deposition was determined by Sirius red staining (A) and its quantification are shown in (B). Original magnification 100 $\times$. (C, D) Expression of α -smooth muscle actin in 9-month-old mice was determined by immunohistochemistry. Quantification (C) and representative pictures (D). Original magnification 320 $\times$. (E) Hepatic messenger RNA expressions of fibrogenic markers, including *Col1A1*, *Acta2*, *Timp1*, and *Tgfb1*, were determined by quantitative real-time polymerase chain reaction in 1-month-old WT, *Tak1^{ΔHep}*, *Tak1/Tgfb2^{ΔHep}*, and *Tgfb2^{ΔHep}* mice. Data are reported as mean $\pm$ standard error of mean. * $P < .05$; ** $P < .01$.

Figure 4.

Additional deletion of *Tgfbr2* in hepatocytes inhibits spontaneous apoptosis and compensatory regeneration in the livers of *Tak1^{ΔHep}* mice. (A) Apoptotic hepatocytes were evaluated by terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining (A, upper) and proliferating hepatocytes were evaluated by immunohistochemistry for proliferation cell nuclear antigen (PCNA) (A, lower) in the livers of WT, *Tak1^{ΔHep}*, *Tak1/Tgfbr2^{ΔHep}*, and *Tgfbr2^{ΔHep}* mice at the 1 month of age (n = 7). Original magnification 320×. (B, C) Quantification for TUNEL staining (B) and staining for PCNA (C). (D) Hepatic messenger RNA expression of apoptotic genes (*Bcl-2*, *Bax*) in the livers of WT, *Tak1^{ΔHep}*, *Tak1/Tgfbr2^{ΔHep}*, and *Tgfbr2^{ΔHep}* mice at 1 month of age was determined by quantitative real-time polymerase chain reaction. (E) Immunoblots for caspase 3, cleaved caspase 3, PCNA, and cyclin D1 in the livers of WT, *Tak1^{ΔHep}*, *Tak1/Tgfbr2^{ΔHep}*, and *Tgfbr2^{ΔHep}* mice at 1 month of age. Data are reported as mean ± standard error of mean. **P* < .05; ***P* < .01.

Figure 5.

Ablation of *Tak1* in hepatocytes abolishes NF- κ B activation and increases susceptibility to TGF- β -mediated apoptosis. (A) Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining (*left*) and its quantification (*right*) in the primary hepatocytes from WT and *Tak1* ^{Δ Hep} mice after incubation with TGF- β 1 (10 ng/mL) for 24 h. Original magnification $\times 320$. (B) Phospho-p38, phospho-JNK, phospho-Smad2, phospho-Smad3, caspase 3, cleaved caspase 3, TAK1, and β -actin were determined by immunoblot analysis after primary hepatocytes from WT and *Tak1* ^{Δ Hep} mice were incubated with TGF- β 1 (10 ng/mL) for the indicated time periods. (C, D) When stimulated with TGF- β (10 ng/mL) for 24 h, NF- κ B was activated in the primary hepatocytes from the NF- κ B-GFP reporter mice with *Tak1* sufficiency and deficiency, and their GFP expression was determined by microscopy (C) and Western blotting (D). Original magnification $\times 400$. (E) Adenoviral-I κ B super repressor inhibited NF- κ B activation, which, as a result, caused apoptosis in primary hepatocytes from WT when stimulated with TGF- β (10 ng/mL) for 24 h. Apoptosis was determined with TUNEL staining. Data are reported as mean $\pm$ standard error of mean. * $P < .05$; ** $P < .01$.

Figure 6.

Inactivation of Smad molecules reduces spontaneous liver injury, inflammation, fibrosis, and HCC in *Tak1*^{ΔHep} mice. (A) Apoptosis in the primary hepatocytes from WT, *Tak1*^{ΔHep}, *Smad4*^{ΔHep}, and *Tak1/Smad4*^{ΔHep} mice after being treated with TGF-β (10 ng/mL) for 24 h were analyzed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining. The number of TUNEL-positive cells was counted. (B–E) WT, *Tak1*^{ΔHep}, and *Tak1/Smad4*^{ΔHep} mice at the age of 1 month (n = 8) were analyzed. (B) Apoptotic hepatocytes evaluated by TUNEL staining (left) and its quantification (lower right). Original magnification 200×. Immunoblots for cleaved caspase 3, caspase 3, Smad4, TAK1, and β-actin are shown (upper right). (C) Serum ALT levels. (D) Hepatic messenger RNA expression of inflammatory genes (*Tnf*, *Il1b*, and *Ccl2*) and fibrogenic genes (*Col1a1*, *Acta2*, and *Tgfb1*) determined by quantitative real-time polymerase chain reaction. (E) Fibrillar collagen deposition was determined by Sirius red staining (left) and its quantification (right). Original magnification ×100. (F) The number of tumors per mouse was counted and the maximum diameter of individual tumor nodules was measured. (WT, n = 10; *Tak1*^{ΔHep}, n = 42; *Tak1/Smad4*^{ΔHep}, n = 15). Data are represented as mean ± standard error of mean. **P* < .05; ***P* < .01.

Figure 7.

Oncogenic gene expression in HCC from *Tak1*^{ΔHep} mice, and TGF- β signaling in DEN-induced murine HCC and in human HCC. (A–D) Liver tissues in 9-month-old WT and *Tgfr2*^{ΔHep} mice, and nontumor liver tissues and tumor tissues in 9-month-old *Tak1*^{ΔHep}, *Tak1/Tgfr2*^{ΔHep} were harvested. (n=7, each samples) (A) Hepatic messenger RNA expression of pro-oncogenes (*Cttnb1*, *Myc*, *Yap1*, and *Wisp1*) was determined by quantitative real-time polymerase chain reaction (qPCR). (B) Hepatic messenger RNA expression of *Bax* and *Bcl-xl* was assessed by qPCR, and protein expression of Bcl-2 and Bcl-xL are shown by immunoblotting. (C, D) Hepatic messenger RNA expressions of *Ctgf* (C), *Vegfa*, and *Vegfr2* (D, upper) were assessed by qPCR. (D, lower) Immunostaining for VEGFa (upper), VEGFR2, and CD31 (lower) are shown. Original magnification 320 $\times$. (E) Diethylnitrosamine was injected (25 mg/kg) in 14-day-old WT and *Tgfr2*^{ΔHep} mice and their livers were harvested at 9 months after DEN injections. Representative macroscopic pictures (left). The number of tumors per mouse was counted and the maximum diameter of individual tumor nodules was measured (right). (WT, n = 16; *Tgfr2*^{ΔHep}, n = 16). NT, nontumor liver, T, tumors. (F) Immunohistochemistry for phospho-Smad2/3 in liver biopsy samples from patients with chronic hepatitis C (n = 4) and in liver tissues from patients with HCC (n = 4). Data are represented as mean $\pm$ standard error of mean. **P* < .05; ***P* < .01.